Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
Status:
Completed
Trial end date:
2019-11-13
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best
supportive care (BSC) versus physician's choice (chosen from a pre-specified list of
therapeutic options) plus BSC.